Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
FY2025 · 10-K disclosure
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 78.44 | Oscillator | Sell |
| Stochastic %K (14, 3, 3) | 94.43 | Oscillator | Sell |
| Williams %R (14) | -3.59 | Oscillator | Sell |
| MACD (12, 26, 9) | 8.19 (Hist 3.11) | Oscillator | Strong Buy |
| Average Directional Index (14) | 30.92 (+DI 38.0 / -DI 12.1) | Trend | Strong Buy |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 22, 26 | Gepsman Martin J | director | S-Sale | 400 @ $302.50 | $121.0K |
| EMA 20 | 285.99 | MA | Strong Buy |
| SMA 20 | 280.26 | MA | Strong Buy |
| EMA 50 | 277.41 | MA | Strong Buy |
| SMA 50 | 277.38 | MA | Strong Buy |
| SMA 200 | 279.41 | MA | Strong Buy |
| Sep 25, 26 |
| Shepard William R |
| director |
| P-Purchase |
| 293 @ $268.76 |
| $78.63K |
| Aug 18, 26 | Shepard William R | director | J-Other | 2,554 | — |
| Aug 18, 26 | Shepard William R | director | J-Other | 2,554 | — |
| Sep 15, 26 | Winkler Julie | officer: Sr MD Chief Commercial Officer | A-Award | 2,864 @ $275.09 | $787.9K |
| Sep 15, 26 | Winkler Julie | officer: Sr MD Chief Commercial Officer | F-InKind | 373 @ $275.09 | $102.6K |
| Sep 15, 26 | Winkler Julie | officer: Sr MD Chief Commercial Officer | F-InKind | 361 @ $275.09 | $99.31K |
| Sep 15, 26 | Winkler Julie | officer: Sr MD Chief Commercial Officer | F-InKind | 320 @ $275.09 | $88.03K |
Stock news · updated daily
Cantor Fitzgerald Investment Advisors L.P. purchased a new stake in CME Group Inc. (NASDAQ: CME) in the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 6,000 shares of the financial services provider's stock, valued at approximately $1,572,000. Other hedge funds have also
The newest inflation update offers a double whammy for the stock market.
On October 22, 2026, CME Group Inc (CME) shares rose 3.5% today, bringing the current price to $305.98. Over the past year, the stock has fluctuated between a 5
Uniswap surged 220% over the summer, landed a historic Wall Street futures listing, and then started bleeding out in October. Whether UNI can claw back to $10 depends on a fragile set of conditions falling into place at once.
CME Group delivers strong revenue and profit growth, but valuation remains elevated, justifying my continued 'hold' rating. Q3 revenue rose 13% to $1.74B, with broad-based volume gains across all product lines, despite a slight decline in average rate per contract. Adjusted net profit margin stands at 62.4%, and net debt is minimal relative to CME's $106B+ market cap, underscoring a low risk profile.
Multicoin Capital just made Hyperliquid its largest hedge fund position, and a fee buyback mechanism quietly purchases HYPE every single day.
Terry Duffy, CME Group CEO, joins 'Power Lunch' to discuss record Q3 revenue, the future of trading, and more.
CME Group Inc. (CME) Q3 2026 Earnings Call Transcript
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Oct 21, 2026 | 2.99 | 3.02 | Beat 1.0% | $1.74B |
| Jul 22, 2026 | 2.91 | 2.99 | Beat 2.7% | $1.71B |
| Apr 22, 2026 | 3.34 | 3.36 | Beat 0.6% | $1.88B |
| Feb 4, 2026 | 2.75 | 2.77 | Beat 0.7% | $1.65B |
| Oct 22, 2025 | 2.63 | 2.68 | Beat 1.9% | $1.54B |
| Jul 23, 2025 | 2.91 | 2.96 | Beat 1.7% | $1.69B |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 10-Q | Oct 23, 2026 | 2026-10-23 14:22:56 | View |
| 4 | Oct 22, 2026 | 2026-10-22 17:39:26 | View |
| 8-K | Oct 21, 2026 | 2026-10-21 07:13:51 | View |
| 4 | Sep 28, 2026 | 2026-09-28 16:15:32 | View |
| 8-K | Sep 25, 2026 | 2026-09-25 16:08:16 | View |
| 4 | Sep 17, 2026 | 2026-09-17 16:29:26 | View |
| 4 | Sep 17, 2026 | 2026-09-17 16:28:38 | View |
| 4 | Sep 17, 2026 | 2026-09-17 16:27:47 | View |
| 4 | Sep 17, 2026 | 2026-09-17 16:26:53 | View |
| 4 | Sep 17, 2026 | 2026-09-17 16:25:59 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | CME | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 25.0x | 25.2x · sector 20.4x | Elevated |
| Forward P/E (FY26E) | 24.7x | EPS est. 12.40 | In line |
| Price / Book | 4.1x | 2.9x | Elevated |
| Price / Sales | 15.8x | 14.3x | In line |
| EV / EBITDA | 16.8x | 17.2x | In line |
| Return on equity | 16.2% | — | Healthy |
| Gross margin | 84.3% | 84.9% | In line |
| Debt / Equity | 0.13 | 0.13 | Conservative |
| Piotroski / Altman Z | 5/9 | Z 0.61 | Distress |
Discounted cash flow model
Current price $306.37
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 22, 26 | Barclays | maintain | Equal Weight | Equal Weight |
| Oct 22, 26 | Morgan Stanley | maintain | Overweight | Overweight |
| Oct 22, 26 | JP Morgan | upgrade | Underweight | Overweight |
| Oct 22, 26 | UBS | maintain | Neutral | Neutral |
| Oct 22, 26 | Piper Sandler | maintain | Overweight | Overweight |
| Oct 22, 26 | Wells Fargo | maintain | Overweight | Overweight |
| Oct 14, 26 | Wells Fargo | maintain | Overweight | Overweight |
| Oct 9, 26 | Morgan Stanley | maintain | Overweight | Overweight |
| Oct 7, 26 | Barclays | maintain | Equal Weight | Equal Weight |